blog

Topics: clinical research, clinical trials, Pharma15, patient data

When it comes to digital health, do you believe that we are past the era of hype and into the era of adoption? Is there a degree of skepticism that still inhibits the wider adoption of digital health solutions in clinical research and healthcare?

Topics: Patient Recruitment, digital health, Digital Platforms, Pharma15

The idea of “digital patient engagement” continues to be one of the hottest topics in the healthcare industry, and according to BBK Worldwide director of innovation Erica Mercado, everyone defines this term in different ways. For instance, apps, wearables, and digital outreach and messaging are all tactics that can be effectively deployed to keep patients engaged. But for Erica, truly effective digital patient engagement amounts to more than the sum of its parts.

Topics: Patient Engagement, digital health, Patient Experience, Pharma15, Vlog

Even when we consider the strict regulations inherent to the healthcare industry, we are still years behind where we should be with regard to the adoption of mobile health technologies. Just look to other highly regulated sectors, like banking and finance; we see that adoption of mobile technology in these industries is much more established.

Topics: mHealth, digital health, Pharma15

There is no doubt that Amazon’s recent acquisition of PillPack – the independent pharmacy and medication distribution system – has major implications not only for the clinical research industry, but the healthcare industry at-large. We asked BBK Worldwide president Matt Kibby to weigh in on Amazon’s foray into the pharmaceutical space. 

Topics: Pharma15, Vlog

With regard to the adoption and use of digital health solutions in clinical R&D, where are we as an industry? In our latest Pharma15 Live! debate, BBK Worldwide founding principal Bonnie A. Brescia posed this question to the panel of industry experts. Justin Johnson, CEO of Biotaware, answered in no uncertain terms: “[the industry] is five to eight years behind where it should be.” Do you agree?

Topics: Pharma15, Most Viewed

While sites should be held accountable for processing the referrals that are generated from clinical trial advertising, it is very important that these referrals are qualified so that sites are not wasting their time. Therefore, generating highly qualified referrals is the number one contributing factor to site engagement.

Do you agree? Disagree? Watch the latest clip from our first episode of Pharma15 Live! and leave a comment below.

Topics: Pharma15

There is a difference between “advertising” to generate referrals for clinical studies and “branding” for clinical trial sites. To remain relevant in a changing media landscape, sites must allocate part of their advertising budget to invest in branding. Do you agree? Disagree? Leave a comment below.

Topics: Pharma15

If regulatory bodies are reviewing advertising and content for digital channels, like social media, should they receive education to understand how these channels work?

Check out the latest clip from our first Pharma15 Live! debate. Do you agree? Disagree? Leave a comment below.

Topics: Social Media, clinical research, Pharma15

When it comes to direct-to-consumer advertising for clinical trials, is it just about generating referrals for sites? Or is the quality of the referral more important than quantity?

Watch this clip from our first Pharma15 Live! debate between industry experts. Do you agree or disagree? Comment below!

Topics: Pharma15